alexa Buprenorphine Maintenance Treatment Of Methamphetamine Dependency | 18041
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Share This Page

Buprenorphine maintenance treatment of methamphetamine dependency

3rd International Conference and Exhibition on Addiction Research & Therapy

Schwann Shariatirad, Alireza Mahjoub, Babak Tofighi and Mohammad Effatpanah

Plenary Session: J Addict Res Ther

DOI: 10.4172/2155-6105.S1.015

Abstract
B uprenorphine, a partial mu-receptor agonist, is a highly effective treatment for opioid dependence successfully introduced in inpatient detoxification units and primary care settings throughout the world. However stressful exposures have been associated with increased cravings and concurrent stimulant abuse (i.e. cocaine and methamphetamine) in office based opioid treatment (OBOT) settings. Recent findings suggest that buprenorphines kappa opioid receptor antagonist activity may decrease stress-induced potentiation of glutamatergic synapses and reduce cocaine craving, an important contributor to relapse. In animal models, methamphetamines dopamine peak effect was reduced after low dose buprenorphine administration; this may be due to buprenorphines agonist effect on nociception/orphanin FQ receptors. In a case series study, we administered buprenorphine to methamphetamine dependent participants and reported significant decreases in methamphetamine cravings and positive methamphetamine urine tests at 12 months. In our current before - after phase II clinical trial study, we will present findings comparing Addiction Severity Index (ASI), cravings, and quality of life before and after buprenorphine administration at 6 months in 21 methamphetamine dependents adults enrolled in outpatient treatment
Biography

Schwann Shariatirad, MD, graduated from Islamic Azad University in Iran and was trained in addiction medicine in SBUMS and QUMS. His current research is focused on introducing novel treatment strategies for methamphetamine dependency. He has collaborated with the UNODC and the anti-narcotics division of Irans National Police force and UNODC and has been a lecturer at Students Research Center of International Campus of Tehran University of Medical Sciences.

Top